The commercialisation company of The University of Queensland (UQ), Australia announced collaboration with Zealand Pharma to identify novel peptide therapeutics inspired by venoms as potential new treatments for gastrointestinal diseases.
The New Zealand Commerce Commission has issued warnings to GlaxoSmithKline and AFT Pharmaceuticals for marketing products which contain the same active ingredients for different indications.
Former Zealand Pharma chief David Horn Solomon, M.D., has taken up the challenge of guiding biotech Akari Therapeutics during an increasingly tumultuous period.
Zealand Pharma (CPH:GEN) is preparing to discuss the future of its hypoglycemia drug with the FDA after pitting the rescue pen against Novo Nordisk’s ($NVO) GlucaGen in Phase II. The data suggest Zealand’s pen achieves clinically relevant increases in plasma glucose in comparable times to GlucaGen, but, notably, its longer shelf life supports ready-to-use formulations.
Up and Down the Ladder: The Latest Comings & Goings at Pfizer, Tekmira and…